Anixa Biosciences receives approval of protocol amendment for ovarian cancer CAR-T clinical trial: San Jose, California Friday, February 21, 2025, 18:00 Hrs [IST] Anixa Bioscience ...

Overview of the Breast Cancer Diagnostics MarketThe Breast Cancer Diagnostics Market plays a pivotal role in the healthcare ...

At just 31 years old, Cameron Gourley had just gotten married when she noticed a lump during her typical self-exam.

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines. To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery ...